Danaher Corporation $DHR Stock: Sivik Global Healthcare LLC Grows Stake

Sivik Global Healthcare LLC lifted its position in Danaher Corporation (NYSE:DHR) by 25.0% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 25,000 shares of the conglomerate’s stock after acquiring an additional 5,000 shares during the quarter. Danaher accounts for approximately 3.4% of Sivik Global Healthcare LLC’s investment portfolio, making the stock its 8th largest holding. Sivik Global Healthcare LLC’s holdings in Danaher were worth $5,539,000 at the end of the most recent quarter.

A number of other hedge funds also recently added to or reduced their stakes in DHR. EP Wealth Advisors LLC acquired a new stake in Danaher in the second quarter worth about $3,807,000. Puzo Michael J acquired a new position in shares of Danaher in the 2nd quarter valued at $8,624,000. Madison Asset Management LLC purchased a new position in shares of Danaher in the second quarter worth about $85,451,000. First Nebraska Trust Co purchased a new position in Danaher during the 2nd quarter worth approximately $14,106,000. Finally, Colton Groome Financial Advisors LLC acquired a new position in Danaher during the third quarter valued at $592,000. 79.05% of the stock is owned by hedge funds and other institutional investors.

Danaher Price Performance

Shares of NYSE:DHR traded up $3.09 during midday trading on Tuesday, reaching $224.29. 2,780,443 shares of the company’s stock traded hands, compared to its average volume of 4,442,988. Danaher Corporation has a 1 year low of $160.93 and a 1 year high of $242.80. The company has a market cap of $157.67 billion, a P/E ratio of 39.85, a PEG ratio of 2.74 and a beta of 0.76. The company has a debt-to-equity ratio of 0.48, a quick ratio of 1.25 and a current ratio of 1.65. The company has a fifty day simple moving average of $211.85 and a two-hundred day simple moving average of $194.88.

Danaher (NYSE:DHR) last issued its quarterly earnings results on Monday, July 20th. The conglomerate reported $1.94 EPS for the quarter, topping the consensus estimate of $1.85 by $0.09. The company had revenue of $6.26 billion during the quarter, compared to analyst estimates of $6.12 billion. Danaher had a net margin of 15.95% and a return on equity of 11.04%. The firm’s revenue was up 5.5% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.77 EPS. Equities analysts predict that Danaher Corporation will post 8.53 EPS for the current fiscal year.

Danaher Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, October 30th. Stockholders of record on Wednesday, September 30th will be given a $0.40 dividend. The ex-dividend date is Wednesday, September 30th. This represents a $1.60 annualized dividend and a dividend yield of 0.7%. Danaher’s dividend payout ratio (DPR) is 28.42%.

Analysts Set New Price Targets

Several research firms recently commented on DHR. Wall Street Zen raised Danaher from a “hold” rating to a “buy” rating in a report on Saturday. UBS Group started coverage on shares of Danaher in a report on Wednesday, September 9th. They set a “buy” rating and a $250.00 target price for the company. Stifel Nicolaus decreased their target price on shares of Danaher from $260.00 to $220.00 and set a “buy” rating for the company in a research note on Wednesday, July 22nd. The Goldman Sachs Group increased their price target on shares of Danaher from $210.00 to $250.00 and gave the stock a “buy” rating in a report on Monday, September 21st. Finally, TD Cowen increased their price target on shares of Danaher from $236.00 to $255.00 and gave the stock a “buy” rating in a report on Tuesday. Two analysts have rated the stock with a Strong Buy rating, seventeen have given a Buy rating and four have given a Hold rating to the company. According to data from MarketBeat, Danaher has an average rating of “Moderate Buy” and an average target price of $235.41.

Danaher Profile

Danaher Corporation (NYSE: DHR) is a global science and technology company that develops and manufactures products, services and solutions for the life sciences, diagnostics and biotechnology industries. Its offerings help researchers, healthcare professionals and biopharmaceutical manufacturers discover, develop, produce and analyze medicines and other biological products.

The company operates through businesses that provide laboratory instruments, consumables, software and services, including technologies for cell analysis, genomics, protein research, bioprocessing and clinical diagnostics.